A Phase 1 Randomized, Open-Label, Parallel-Group, Active- and Placebo-Controlled Study to Assess Safety and Tolerability of 60, 120, and 200 mc Meningococcal Group B rLP2086 Vaccine in Healthy Adult Subjects

Trial Profile

A Phase 1 Randomized, Open-Label, Parallel-Group, Active- and Placebo-Controlled Study to Assess Safety and Tolerability of 60, 120, and 200 mc Meningococcal Group B rLP2086 Vaccine in Healthy Adult Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 17 Dec 2014

At a glance

  • Drugs PF 5212366 (Primary) ; DTaP vaccine
  • Indications Diphtheria; Meningococcal group B infections; Pertussis; Tetanus
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors Pfizer
  • Most Recent Events

    • 31 Jul 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 18 Jul 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 12 Jan 2012 Planned number of patients changed from 48 to 50 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top